It is known that transient receptor potential cation channel subfamily V member 3 (TRPV3) is crucial for the modulation of skin homeostasis by regulation of Ca2+.
Bristol Myers Squibb Co. has exercised its option for an exclusive global license for PRX-019, a potential treatment of neurodegenerative diseases with an undisclosed target, under an agreement with Prothena Corp. plc.
C-C chemokine receptor type 6 (CCR6) regulates the migration and recruitment of T cells in inflammatory and immunological processes and, as part of the CCR6-CCL20 axis together with its exclusive binding molecule CCL20, plays a critical role in maintaining immunological homeostasis during inflammation and infection.
Genetic deletion of protease-activated receptor 4 (PAR4) in experimental models has been linked to improvement in neurological dysfunction and reduction of infarct volume in the context of stroke. Moreover, pretreatment with PAR4 antagonists in models of traumatic brain injury has shown protection against secondary tissue injury and thrombo-inflammatory activation.
A group of scientists from Basel University Hospital have designed an antibody-drug conjugate (ADC) that eliminated blood cancer cells without attacking healthy hematopoietic stem cells (HSCs), which they modified by base editing and transplanted to renew an altered blood system. They achieved this by focusing on the panhematopoietic marker CD45.
Mast/stem cell growth factor receptor KIT is a receptor tyrosine kinase that plays a key role in mast cell differentiation, proliferation, survival and activation.
Transthera Biosciences Co. Ltd. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of autoimmune disease, inflammatory disorders and immunological disorders.
Novo Nordisk A/S has identified C-type natriuretic peptide (CNP) compounds reported to be useful for the treatment of achondroplasia and heart failure.
Scientists at Shanghai Synergy Pharmaceutical Sciences Co. Ltd. and Zhejiang Huahai Pharmaceutical Group Co. Ltd. have synthesized non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, inflammatory bowel disease (IBD) and lupus erythematosus.
RSS
